QPPV.COM KNOWLEDGE ASSESSMENT

Infliximab: History, Classification, Mechanism of Action, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Infliximab: History, Classification, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which exposure pattern is generally most likely to promote anti-drug antibody formation?

Regular maintenance administration without interruptions Episodic treatment or prolonged interruptions between courses Continuous exposure with stable trough concentrations Administration with an immunomodulator in a relevant population

Question 2 of 10 Why is the distinction between soluble and transmembrane TNF relevant to understanding infliximab's effects?

Infliximab binds only soluble TNF, so membrane-associated TNF is pharmacologically irrelevant Binding to transmembrane TNF may affect local signalling and permit Fc-mediated cellular effects in appropriate contexts Transmembrane TNF is converted into an intracellular kinase after infliximab binding Binding to soluble TNF prevents antibody formation, whereas membrane binding causes it

Question 3 of 10 A patient develops dyspnoea during an infliximab infusion. Which approach is most appropriate?

Automatically code the event as anaphylaxis Assume it is heart failure because infliximab is associated with cardiac risk Consider hypersensitivity, volume effects, ischaemia, heart failure and other causes while documenting objective findings Exclude an infliximab relationship unless the patient has a positive tryptase result

Question 4 of 10 Why should pregnancy and infant exposure reports record the trimester and date of the last infliximab infusion?

Placental transfer of IgG1 increases later in pregnancy, making timing relevant to fetal and infant exposure Infliximab cannot cross the placenta during any trimester The last infusion date determines the infant's genetic sex Trimester information is relevant only to infusion-site reactions in the mother

Question 5 of 10 Which set of data would be most valuable when evaluating an acute infliximab infusion reaction?

Only the patient's age and indication Infusion rate, timing, clinical phenotype, vital signs, prior interruptions, treatment and outcome Only the batch number and expiry date Only the patient's baseline C-reactive protein

Question 6 of 10 What is the primary pharmacological mechanism of infliximab?

Direct inhibition of intracellular Janus kinases Competitive blockade of TNFR1 and TNFR2 by binding to the receptors Neutralisation of soluble and transmembrane TNF, reducing productive TNF-receptor signalling Depletion of all circulating T lymphocytes through CD20 binding

Question 7 of 10 Which statement best reflects appropriate causality assessment when a patient develops a serious infection during infliximab treatment?

The infection is automatically caused by infliximab because TNF blockade is an identified risk Causality should consider exposure, latency, pathogen, disease-related risk, concomitant immunosuppression and alternative explanations A lack of rechallenge disproves a causal relationship Only the time since the last infusion is relevant

Question 8 of 10 A patient develops fever, rash, arthralgia and facial oedema several days after restarting infliximab following a long treatment interruption. What is the most appropriate initial interpretation?

The pattern is compatible with a delayed serum-sickness-like reaction and warrants structured evaluation The timing excludes any relationship to infliximab The event is necessarily an IgE-mediated anaphylactic reaction The symptoms prove that the patient has developed lupus

Question 9 of 10 Which description most accurately characterises infliximab's molecular structure?

A fully human, Fc-free Fab fragment directed against TNF A chimeric human-murine, bivalent IgG1 monoclonal antibody with an intact Fc region A soluble TNF-receptor and human Fc fusion protein A multispecific antibody directed against TNF and TNFR2

Question 10 of 10 Which combination best describes the clinically important consequences of anti-infliximab antibodies?

Increased trough concentrations, reduced clearance and lower infusion-reaction risk Accelerated clearance, lower trough concentrations, reduced response and increased infusion-reaction risk Improved adherence, reduced infection risk and increased disease specificity Direct TNF receptor activation and predictable therapeutic improvement

QPPV.com

Infliximab: History, Classification, Mechanism of Action, Safety and Pharmacovigilance

Cookie Settings